@xconomy.com 3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com 3 years ago
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity
@xconomy.com 3 years ago
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity
@xconomy.com 3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com 3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com 3 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com 4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com 4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com 4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com 4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com 4 years ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com 4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com 4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com 4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com 4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com 5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com 5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com 5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com 5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com 5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com 5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com 5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com 5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com 5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com 5 years ago
Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison & Honjo
@xconomy.com 5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com 5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com 5 years ago
Startup CureMatch Wins $35,000 Grand Prize in Global Trade Pitchfest
@xconomy.com 5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More